Fig. 4

UCCs sensitivity towards short-term treatment with cisplatin is not correlated with abundance of CD90⁺ cells. a Cell viability was measured 72 h after cisplatin treatment by MTT assay in 11 UCCs, categorized into UCCs with epithelial (dark grey bars) and mesenchymal (light grey bars) phenotypes. b Subsequent to short-term treatment with cisplatin (STT, 72 h) most cell lines displayed increased numbers of CD90+ cells. Mean percentages of CD90⁺ cells in untreated (dark grey bars) and STT (dark grey bars, shades), CD44⁺ cells in untreated (light grey bars) and STT (light grey bars, shades), and CD49f⁺ cells in untreated (grey bars) and STT (grey bars, shades) UCCs as measured by flow cytometry. c) Relative expression of CK14, CK5, and CK20 was measured by qRT-PCR in a panel of 11 untreated and STT-UCCs. Expression in the respective untreated control cells was set as 1. Data represent the mean ± SD of three independent experiments. SDHA was used as reference gene and relative expression calculated by using the 2^−ΔΔCT method. Untr Ctrl untreated control, STT short-term cisplatin treatment. *P <0.05; **P <0.001